chemical

Upadacitinib ABT-494

HY-19569

10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 200 mg; 500 mg; 1 g; 5 g

50; 110; 160; 280; 390; 550; 850; 1500; 2000; 5000 USD

Upadacitinib ABT-494

Chemical

10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 200 mg; 500 mg; 1 g; 5 g

50; 110; 160; 280; 390; 550; 850; 1500; 2000; 5000 USD

Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 ( JAK1 ) inhibitor ( IC 50 =43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) is used in development for the treatment of several autoimmune disorders [1] [2] .

99.96%

Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 6 months; -20°C, 1 month.